

- Schmidt J, Ryschich E, Mayer H, Gebhard MM, Herfarth C, Klar E** 1.5  
 Loss of CD11b/CD18-associated leucocyte adherence stimulation with platelet-activating factor (PAF) and f-MLP in malignant tumor endothelium of experimental rat pancreatic cancer.  
 Langenbecks Arch Chir 1998, 115 (Suppl.1): 413-419
- Schmidt J, Ryschich E, Mayer H, Gebhard MM, Herfarth C, Klar E 19 7.7  
 [Lack of stimulation of CD11b/CD18 induced leukocyte adhesion by platelet activating factor (PAF) and f-MLP in malignant tumor endothelium in experimental pancreas cancer of the rat].  
 Langenbecks Arch Chir Suppl Kongressbd 1998, 115:413-419
- Schmidt J, Ryschich E, Maksan SM, Werner J, Gebhard MM, Herfarth C, Klar E 8 1.2  
 Reduced basal and stimulated leukocyte adherence in tumor endothelium of experimental pancreatic cancer.  
 Int J Pancreatol 1999, 26: 173-179
- Schmidt J, Ryschich E, Maksan SM, Werner J, Gebhard MM, Herfarth C, Klar E 3 1.4  
 Influence of gastrointestinal hormones on tumor microcirculation of experimental pancreatic cancer in the rat.  
 Digest Surg 2000, 17: 250-255
- Schmidt J, Ryschich E, Daniel V, Herzog L, Werner J, Herfarth C, Longnecker DS, Gebhard MM, Klar E 13 0.8  
 Vascular structure and microcirculation of experimental pancreatic carcinoma in rats.  
 Eur J Surg 2000, 166: 328-335
- Eisold S, Schmidt J, Antolovic D, Leutloff U, Libicher M, Klar E  
 [The intra-arterial calcium stimulation test in site diagnosis for surgical therapy of insulinoma].  
 Chirurg 2000, 71:1236-1242
- Eisold S, Linnebacher M, Ryschich E, Schmidt J, Klar, E Herfarth C, v. Knebel-Doeberitz M 1.5  
 Synergistic effect of p53 adenovirus-mediated gene therapy and 5-FU chemotherapy in vitro and in vivo against experimental pancreatic cancer.  
 Langenbecks Arch Chir 2001, 118 Suppl. 1: 159-161
- Ryschich E, Schmidt J, Loeffler T, Gebhard MM, Harms W, Klar E 1.5  
 Unterschiedliche Effekte der Bestrahlung im gesunden Pankreas und im Pankreaskarzinom der Ratte.  
 Chir Forum 2002, 31:227-229
- Eisold S, Dihlmann S, Linnebacher M, Ryschich E, Aulmann M, Schmidt J, Schlehofer J, Ridder R, von Knebel-Doeberitz M 1 4.7  
 Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2.  
 Int J Cancer 2002, 100: 606-614

- Rieder H, Sina-Frey M, Ziegler A, Hahn SA, Przypadlo E, Kress R, Gerdtes B, Colombo-Benkmann M, Eberl T, Grützmann R, Lörken M, Schmidt J, Bartsch DK 8 1.72  
German National Case Collection of Familial Pancreatic Cancer – Clinical genetic analysis of the first 21 families.  
Onkologie 2002, 25: 262-266
- Ryschich E, Werner J, Gebhard MM, Klar E, Schmidt J 7 1.6  
Angiogenesis inhibition with TNP-470, 2-methoxyestradiol and paclitaxel in experimental pancreatic carcinoma.  
Pancreas 2003, 26:166-172
- Ryschich E, Harms W, Loeffler T, Eble M, Gebhard MM, Klar E, Schmidt J 7 4.7  
Radiation-induced leukocyte adhesion to endothelium in normal pancreas and in pancreatic carcinoma of the rat.  
Int J Cancer 2003, 105:506-511
- Ryschich E, Schmidt J, Loeffler T, Harms W, Eble M, Gebhard MM, Klar E 3 7.7  
Different radiogenic effects on microcirculation in healthy pancreas and pancreatic carcinoma of the rat.  
Ann Surg 2003, 237:515-521
- Ryschich E, Autschbach F, Eisold S, Klar E, Büchler MW, Schmidt J 2.46  
Expression of HLA-class I/II antigens and T cell immune response in human neuroendocrine tumors of the pancreas.  
Tissue Antigens 2003, 62:48-54
- Ryschich E, Autschbach F, Noetzel T, Hinz U, Klar E, Büchler MW, Schmidt J 1.5  
The role of HLA Class I in the T-cell induced immune response in human pancreatic carcinoma  
Chir Forum 2003, 32:105-107
- Schneider C, Schmidt T, Ziske C, Tiemann K, Lee KM, Uhlinsky V, Behrens P, Sauerbruch T, Schmidt-Wolf IGH, Mühlradt PF, Schmidt J, Märten A 3 9  
Tumor suppression induced by the Macrophage activating lipopeptide MALP-2 in an ultrasound-guided pancreatic carcinoma mouse model.  
Gut 2004, 53: 355-361
- Ryschich E, Huszty G, Knaebel HP, Hartel M, Büchler MW, Schmidt J. 6 4.17  
Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas.  
Eur J Cancer 2004, 40:1418-1422
- Bartsch DK, Kress R, Sina-Frey M, Grutzmann R, Gerdes B, Pilarsky C, Heise JW, Schulte KM, Colombo-Benkmann M, Schleicher C, Witzigmann H, Pridohl O, Ghadimi M, Horstmann O, v.Berndorff W, Jochimsen L, Schmidt J, Eisold S, Estevez-Schwarz L, Hahn SA, Schulmann K, Bock W, Gress T, Zigel N, Breitschaft K, Prenzel K, Messmann H, Endlicher E, Schneider M, Ziegler A, Schmiegel W, Rothmund M, Rieder H 5 4.7  
Prevalence of familial pancreatic cancer in Germany.  
Int J Cancer 2004, 110:902-906

Ryschich E, Schmidt E, Maksan SM, Klar E, Schmidt J Expansion of endothelial surface by an increase of vessel diameter during tumor angiogenesis in experimental pancreatic and hepatocellular cancer. World J Gastroenterol 2004, 10:3171-3174	3 3.3
Weitz J, Koch M, Kleeff J, Müller MW, Schmidt J, Friess H, Büchler MW [Kausch-Whipple pancreaticoduodenectomy. Technique and results]. Chirurg 2004, 75:1113-1119	
Eisold S, Ryschich E, Nauheimer D, Giese T, Linnebacher M, Wild A, Bartsch D, Büchler MW, Schmidt J Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background. Cancer 2004, 100:1978-1986	1 4.6
Eisold S, Linnebacher M, Ryschich E, Antolovic D, Hinz U, Klar E, Schmidt J The effect of adenovirus expressing wild-type p53 on 5-Fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J Gastroenterol 2004, 10:3583-3589	2 3.3
Schmidt J, Eisold S, Buchler MW, Märten A Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother 2004, 53:1018-1026	2 4.3
Ryschich E, Cebotari O, Fabian OV, Autschbach F, Kleef J, Friess H, Bierhaus A, Buchler MW, Schmidt J Loss of heterozygosity in the HLA class I region in human pancreatic cancer. Tissue Antigens 2004, 64:696-702	1 2.9
Eisold S, Linnebacher M, Ryschich E, Antolovic D, Hinz U, klar E, Schmidt J The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J Gastroenterol. 2004, 10:3583-9	2 3.3
Ryschich E, Jesnowski R, Ringel J, Harms W, Fabian OV, Saller R, Schrewe M, Engel A, Schmidt J, Lohr M Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: low-dose ifosfamide and local tumor irradiation. Int J Cancer 2005, 113:649-653	2 4.7
Ma J, Patrut E, Schmidt J, Knaebel HP, Büchler MW, Märten A Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. World J Gastroenterol 2005, 14:1521-1528	3.3

<p>Ryschich E, Huszty G, Wentzensen N, Weitz J, Knaebel HP, Schmidt E, Büchler MW, Märten A, Schmidt J (2005)  Therapeutischer Effekt des Gentransfers von FLT-3 Ligand beim experimentellen Pankreaskarzinom.  Chir Forum 34:125-126</p>	<p>1.5</p>
<p>Ryschich E, Notzel T, Hinz U, Autschbach F, Ferguson J, Simon I, Weitz J, Fröhlich B, klar E, Büchler MW, Schmidt J  Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma  Clin Cancer Res 2005, 11:498-504</p>	<p>6.18</p>
<p>Mehrle S, Frank S, Schmidt J, Schmidt-Wolf IG, Märten A  SAP and SLAM expression in anti-CD3 activated lymphocytes correlates with cytotoxic activity.  Immunol Cell Biol 2005, 83:33-39</p>	<p>2.5</p>
<p>Knaebel HP, Märten A, Schmidt J, Hoffmann K, Seiler C, Lindel K, Schmitz-Winnenthal H, Fritz S, Goldschmidt H, Mansmann U, Debus J, Diehl V, Buechler MW  Phase III trial of postoperative cisplatin, interferon alpha 2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].  BMC Cancer 2005, 12;5:37</p>	<p>1 2.36</p>
<p>Schmidt J, Klempp C, Büchler MW, Maerten A  Release of iC3b from apoptotic pancreatic tumor cells induces tolerance by binding to immature dendritic cells in vitro and in vivo.  Cancer Immunol Immunother 2006, 55:31-38</p>	<p>4.3</p>
<p>Schmidt J, Ryschich E, Sievers E, Schmidt-Wolf IG, Büchler MW, Märten A  Telomerase-specific T-cells kill pancreatic tumor cells in vitro an in vivo  Cancer 2006, 106:759-764</p>	<p>4.6</p>
<p>Hoffmann K, Mehrle S, Maerten A, Büchler MW, Schmidt J (2006)  Multi-Drug Resistance: Induktion und Inhibition beim Pankreaskarzinom  Chir Forum 35:157</p>	<p>1.5</p>
<p>Ryschich E, Huszty G, Wentzensen N, Schmidt E, Knaebel HP, Encke J, Märten A, Buchler MW, Schmidt J  Effect of Flt3 ligand gene transfer in experimental pancreatic cancer.  Int J Colorectal Dis 2006, 22: 215-223</p>	<p>2</p>
<p>Schmidt J, Jäger D, Buchler MW, Märten A  Impact of Interferon-Alpha in combined chemoradioimmuno-therapy for pancreatic adenocarcinoma (CapRI): First data from the immunomonitoring  J Immunother 2006, 30:108-115</p>	<p>4.5</p>

- Märten A, von Lilienfeld-Toal M, Büchler MW, **Schmidt J** 4.7  
Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gamma delta T cell cytotoxicity.  
Int J Cancer 2006, 119: 2359-2365
- Schmidt J**, Patrut E, Ma J, Jager D, Knaebel H-P, Buchler MW, Marten A 4.3  
Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI).  
Cancer Immunol Immunother 2006, 55: 1396-1405
- Hoffmann K, Marten A, Lindel K, Fritz S, Jager D, Buchler MW, Schmidt J 2.4  
Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature [ISRCTN62866759].  
BMC Cancer 2006, 6:128
- Welsch T, Mechttersheimer G, Aulmann S, Müller SA, Büchler MW, Schmidt J, Kienle P  
Huge primitive neuroectodermal tumor of the pancreas: report of a case and review of the literature.  
World J Gastroenterol 2006, 12:6070-6073
- Welsch T, Hallscheidt P, **Schmidt J**, Steinhardt HJ, Büchler MW, Sido B  
Management of a rare case of fulminant hemobilia due to arteriobiliary fistula following total pancreatectomy.  
J Gastroenterol 2006, 41:1116-1119
- Schmied BM, Sauer P, Mehrabi A, Welsch T, Büchler MW, Zeier M, **Schmidt J**  
Immunosuppressive standards in simultaneous kidney-pancreas transplantation.  
Clin Transplant. 2006, 20:44-50

- Eisold S, Antolovic D, **Schmidt J**, Wiessner R, Klar E, von Knebel-Doeberitz M, Linnebacher M 0.7  
 Effective antitumoral responses are not induced by cytosine deaminase suicide gene transfer in a syngeneic rat pancreatic carcinoma model.  
 Eur Surg Res 2006, 38: 513-521
- Shrikande SV, Kleef J, Reiser C, Weitz J, Hinz U, Esposito I, Schmidt J, Friess H, Buchler MW 3.3  
 Pancreatic resections for M1 pancreatic ductal adenocarcinoma.  
 Ann Surg Oncol 2007, 14: 118-127
- Weitz J, Kienle P, Schmidt J, Friess H, Buehler MW  
 Portal vein resection for advanced pancreatic head cancer.  
 J Am Coll Surg 2007, 204:712-716
- Schmidt J, Jäger D, Hoffmann K, Buehler MW, Märten A  
 Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring.  
 J Immunother 2007, 30:108-115
- Märten A, Lilienfeld-Toal M, Buehler MW, Schmidt J 4.5  
 Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells.  
 J Immunother 2007, 30:370-377
- Schmidt J, Welsch T, Jäger D, Muehlrad Pf, Buehler MW, Märten A 4.1  
 Intratumoural injection of the toll-like receptor -2/6 agonist' macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial.  
 Br J Cancer 2007, 97: 598-604
- Welsch T, Endlich K, Giese T, Buchler MW, Schmidt J 2.9  
 Eps8 is increased in pancreatic cancer and required for dynamic actin-based cell protrusions and intercellular cytoskeletal organization.  
 Cancer Lett. 2007, 255:205-18

- Eisold S, **Schmidt J**, Ryschich E, Gock M, Klar E, von Knebel-Doeberitz M, Linnebacher M 2.1  
 Induction of an antitumoral immune response by wild-type Adeno-Associated Virus type 2 (AAV-2) in an in vivo model of pancreatic carcinoma  
 Pancreas. 2007, 35:63-72.
- 200.Mehrle S, Schmidt J, Büchler MW, Watzl C, Märten A. 4.8  
 Enhancement of anti-tumor activity in vitro and in vivo by CD150 and SAP.  
 Mol Immunol. 2007, 45:796-804
- Serba S, Schmidt J, Wentzensen N, Ryschich E, Märten A. 9,0  
 Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma.  
 Gut 2007 (in press)
- Welsch T, Frommhold K, Kleeff J, Hinz U, Friess H, Buchler MW, Schmidt J 3.0  
 Persisting elevation of C-reactive protein after pancreatic resections can indicate developing inflammatory complications  
 Surgery 2007 (in press)
- Mood ZA, Mehrabi A, Schmied BM, Müller SA, Engelmann H, Schemmer P, Weitz J, Büchler MW, Gebhard MM, Schmidt J  
 Review of various techniques of pancreas transplantation in rat model.  
 J Surg Res 2008, 145:205-213
- Morath C, Zeier M, Döhler B, Schmidt J, Nawroth PP, Opelz G 7.37  
 Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes.  
 J Am Soc Nephrol. 2008, 8:200-201
- Zhu Y, Tibensky I, Schmidt J, Ryschich E, Märten A 1.5  
 Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.  
 J Immunother 2008, 31:599-606
- Zhu Y, Tibensky I, Schmidt J, Hackert T, Ryschich E, Jäger D, Büchler MW, Märten A. 3.06  
 Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.  
 J Immunother. 2008, 31(1):28-33
- Mehrle S, Schmidt J, Büchler MW, Watzl C, Märten A. 3.97  
 Enhancement of anti-tumor activity in vitro and in vivo by CD150 and SAP.  
 Mol Immunol. 2008, 45:796-804

Hoffmann K, Bekeredjian R, Schmidt J, Büchler MW, Märten A. Effects of the high-affinity Peptide reversin 121 on multidrug resistance proteins in experimental pancreatic cancer. Tumour Biol. 2008, 29(6):351-8	4.51
Märten A, Zeiss N, Serba S, Mehrle S, von Lilienfeld-Toal M, Schmidt J. Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma. Mol Cancer Ther. 2008, 7(11):3624-31.	2.04
Welsch T, Frommhold K, Hinz U, Weigand MA, Kleeff J, Friess H, Büchler MW, Schmidt J Persisting elevation of C-reactive protein after pancreatic resections can indicate developing inflammatory complications. Surgery 2008, 143:20-28	4.77
Welsch T, Büchler MW, Schmidt J [Surgery for pancreatic cancer]. Z Gastroenterol 2008, 46:1393-1403	
Gaida MM, Günther F, Wagner C, Friess H, Giese NA, Schmidt J, Hänsch GM, Wente MN Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections. Clin Exp Immunol 2008, 154: 216-223	4.09
Fonouni H, Mehrabi A, Soleimani M, Müller SA, Büchler MW, Schmidt J The need for venovenous bypass in liver transplantation. HPB (Oxford) 2008, 10(3):196-203.	1.5
Hoffmann K, Mehrle S, Schmidt J, Büchler MW, Märten A. Interferon-alpha restitutes the chemosensitivity in pancreatic cancer. Anticancer Res. 2008, 28(3A):1499-507.	0.49
Märten A, Wente MN, Ose J, Büchler MW, Rötzer I, Decker-Baumann C, Karapanagiotou-Schenkel I, Harig S, Schmidt J, Jäger D An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinical benefit - PANUSCO. BMC Cancer. 2009, 9:412.	0.49
Ryschich E, Khamidjanov A, Kerkadze V, Büchler MW, Zöller M, Schmidt J Promotion of tumor cell migration by extracellular matrix proteins in human pancreatic cancer.	3.57



Pancreas. 2009, 38(7):804-10.

Kulu Y, Schmied BM, Werner J, Muselli P, Büchler MW, Schmidt J  
Total pancreatectomy for pancreatic cancer: indications and operative technique. HPB (Oxford). 2009, 11(6):469-75. 0.96

Welsch T, Keleg S, Bergmann F, Bauer S, Hinz U, Schmidt J  
Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma.  
Pancreas. 2009, 38(8):968-76.

Mehrle S, Watzl C, von Lilienfeld-Toal M, Amoroso A, Schmidt J, Märten A  
Comparison of phenotype of gammadelta T cells generated using various cultivation methods.  
Immunol Lett. 2009, 125(1):53-8. Epub 2009 Jun 6.

Welsch T, Keleg S, Bergmann F, Degrade L, Bauer S, Schmidt J.  
Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma.  
Clin Exp Metastasis. 2009, 26(7):701-11.

Märten A, Schmidt J, Ose J, Harig S, Abel U, Münter MW, Jäger D, Friess H, May J, Adler G, Seufferlein T, Gress T, Schmid R, Büchler MW.  
A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2.  
BMC Cancer. 2009, 9:160.

Sorg C, Schmidt J, Büchler MW, Edler L, Märten A  
Examination of external validity in randomized controlled trials for adjuvant treatment of pancreatic adenocarcinoma.  
Pancreas. 2009, 38(5):542-50.

Wente MN, Schmied BM, Schmidt J, Büchler MW  
[Differentiated therapy for intraductal papillary mucinous neoplasms].  
Chirurg 2009, 80:7-13

Morath C, Schmied BM, Mehrabi A, Weitz J, Schmidt J, Werner J, Büchler MW, Morcos M, Nawroth PP, Schwenger V, Döhler B, Opelz G, Zeier M  
Simultaneous pancreas-kidney transplantation in type 1 diabetes.  
Clin Transplant 2009, 23:115-120

Hassanin H, Serba S, Schmidt J, Märten A  
Ex vivo expanded telomerase-specific T cells are effective in an orthotopic mouse model for pancreatic adenocarcinoma.  
Clin Exp Immunol 2009, 158:125-132

Welsch T, Younsi A, Disnza A, Rodriguez JA, Cuervo AM, Scita G, Schmidt J  
Eps8 is recruited to lysosomes and subjected to chaperone-mediated autophagy in cancer cells.

Exp Cell Res 2010, 316:1914-1924

Gaida MM, Haag N, Günther F, Tschaharganeh DF, Schirmacher P, Friess H, Giese NA, Schmidt J, Wente MN  
Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma.  
Int J Mol Med. 2010, (2):281-8.

Hackert T, Werner J, Weitz J, Schmidt J, Büchler MW  
Uncinate process first--a novel approach for pancreatic head resection.  
Langenbecks Arch Surg. 2010, 395:1161-1164

Märten A, Büchler MW, Werft W, Wente MN, Kirschfink M, Schmidt J  
Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology.  
J Immunother. 2010, 33(2):219-24.

Morath C, Zeier M, Döhler B, Schmidt J, Nawroth PP, Schwenger V, Opelz G  
Transplantation of the type 1 diabetic patient: the long-term benefit of a functioning pancreas allograft.  
Clin J Am Soc Nephrol. 2010, 5(3):549-52.

Bazhin AV, De Smet C, Golovastova MO, Schmidt J, Philippov PP  
Aberrant demethylation of the recoverin gene is involved in the aberrant expression of recoverin in cancer cells.  
Exp Dermatol. 2010 (In Press)

Heller A, Zörnig I, Müller T, Giorgadze K, Frei C, Giese T, Bergmann F, Schmidt J, Werner J, Buchler MW, Jaeger D, Giese NA  
Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer.  
Cancer Immunol Immunother. 2010, 59(9):1389-400..

Welsch T, Degrate L, Zschäbitz S, Hofer S, Werner J, Schmidt J  
300.The need for extended intensive care after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.  
Langenbecks Arch Surg. 2011, 396:353-362

Welsch T, von Frankenberg M, Schmidt J, Büchler MW  
[Diagnosis and definition of anastomotic leakage from the surgeon's perspective].  
Chirurg 2011, 82:48-55

Hartwig W, Werner J, Mayer H, Ryschich E, Schmidt J, Gebhard MM, Herfarth Ch, Klar E 11 2.1  
Cigarette smoke enhances ethanol-induced pancreatic injury.  
Pancreas 2000, 21: 272-279

Paramythiotis D, Kleeff J, Schmidt J, Büchler MW, Friess H  
Detection of oncogenes in chronic pancreatitis.  
HPB (Oxford) 2003, 5:214-225

- Mayer H, Thies J, **Schmidt J**, Gebhard MM, Herfarth C, Klar E 1.5  
 Verminderung des Reperfusionsschadens durch N-Acetylcystein bei  
 experimenteller Pankreastransplantation. Decreasing reperfusion damage with  
 N-acetylcysteine in experimental pancreas transplantation.  
 Langenbecks Arch Chir 1998, 115 Suppl 1: 147-151
- Mayer H, Schmidt J, Thies J, Ryschich E, Gebhard MM, Herfarth C, Klar E 17 1.8  
 Characterization and reduction of ischemia/reperfusion injury after experimental  
 pancreas transplantation.  
 J Gastrointest Surgery 1999, 3: 162-166
- Hackert T, Werner J, Uhl W, Gebhard MM, Büchler MW, Schmidt J 1 2.1  
 Reduction of ischemia/reperfusion injury by antithrombin III after experimental  
 pancreas transplantation.  
 Am J Surg 2005, 189:92-97

- Schmidt J**, Rattner DW, Lewandrowski K, Compton CC, Mandavilli U, Warsaw AL 132 7.7  
A better model of acute pancreatitis for evaluating therapy.  
Ann Surg 1992, 215: 44-56
- Schmidt J**, Fernandez-del Castillo C, Rattner DW, Lewandrowski K, Compton CC, Jehanli A, Hermon-Taylor J, Warsaw AL 67 12.5  
Trypsinogen-activation peptides in experimental rat pancreatitis: Prognostic implications and histopathologic correlates.  
Gastroenterology 1992, 103: 1009-1016
- Schmidt J**, Lewandrowski K, Rattner DW, Mandavilli U, Compton CC, Warsaw AL 34 1.2  
Morphometric characteristics and homogeneity of a new model of acute pancreatitis in the rat.  
Int J Pancreatol 1992, 12: 41-51
- Schmidt J**, Lewandrowski K, Fernandez del Castillo C, Rattner DW, Mandavilli U, Compton CC, Warsaw AL 23 1.5  
Histopathologic correlates of serum amylase activity in experimental pancreatitis.  
Dig Dis Sci 1992, 37: 1426-1433
- Fernandez-del Castillo C, **Schmidt J**, Rattner DW, Mandavilli U, Lewandrowski K, Compton CC, Jehanli A, Patel G, Hermon-Taylor J, Warsaw AL 27 2.1  
Generation and possible significance of trypsinogen activation peptides in experimental acute pancreatitis in the rat.  
Pancreas 1992, 7: 263-270
- Wickerts CJ, Berg B, Frostell C, **Schmidt J**, Blomqvist H, Rösblad PG, Kihlström I, Messmer K, Hedenstierna G (1992) 4 2.6  
Influence of hypertonic-hyperoncotic solution and furosemide on canine hydrostatic pulmonary oedema resorption.  
J Physiol (London) 458: 425-438
- Schmidt J**, Fernandez-del Castillo C, Rattner DW, Lewandrowski K, Messmer K, Warsaw AL 22 2.1  
Hyperoncotic ultrahigh molecular weight dextran solutions reduce trypsinogen activation, prevent acinar necrosis, and lower mortality in rodent pancreatitis.  
Am J Surg 1993, 165: 40-45
- Huch K, **Schmidt J**, Sinn HP, Schratt W, Klar E, Buhr HJ 1.5  
Parenchymprotektive Wirkung von hyperonkotischen Dextranen nach verzögertem Therapiebeginn bei nekrotisierender Pankreatitis der Ratte.  
Langenbecks Arch Chir 1993, 110 (Suppl.1): 223-226
- Ryan CM, **Schmidt J**, Mandavilli U, Lewandrowski K, Compton CC, Rattner DW, Warsaw AL, Tompkins RG 55 12.5  
Gut macromolecular permeability in pancreatitis correlates with severity of disease in rats.  
Gastroenterology 1993, 104: 890-895

Fernandez-del Castillo C, <b>Schmidt J</b> , Rattner DW, Warshaw AL Interstitial protease activation is the central event in progression to necrotizing pancreatitis. Surgery 1994, 116: 497-504	44 2.98
Foitzik T, Bassi DG, <b>Schmidt J</b> , Lewandrowski K, Fernandez-del Castillo C, Rattner DW, Warshaw AL Intravenous contrast medium accentuates the severity of acute necrotizing pancreatitis in the rat. Gastroenterology 1994, 106: 207-214	59 12,5
Hotz HG, <b>Schmidt J</b> , Foitzik T, Ryschich E, Buhr HJ, Herfarth C, Klar E Intravenöse Kontrastmittel verstärken die Mikrozirkulationsstörung des Pankreas bei experimenteller nekrotisierender Pankreatitis. Langenbecks Arch Chir 1994, 111 (Suppl. 1) 293-295	1.5
<b>Schmidt J</b> , Rattner DW, Lewandrowski K, Compton CC, Warshaw AL Late histopathologic changes and healing in an improved rodent model of acute necrotizing pancreatitis. Digestion 1995, 56: 246-252	4 1.8
<b>Schmidt J</b> , Hotz HG, Foitzik T, Ryschich E, Buhr HJ, Warshaw AL, Herfarth C, Klar E Intravenous contrast medium aggravates the impairment of pancreatic microcirculation in necrotizing pancreatitis in the rat. Ann Surg 1995, 221: 257-264	44 7.7
Schmidt J, Hotz HG, Langer C, Buhr HJ, Herfarth C, Klar E: Dextran induziert eine spezifische Verbesserung der reduzierten Pankreasmikrozirkulation bei experimenteller nekrotisierender Pankreatitis. Langenbecks Arch Chir 1995, 112 (Suppl) 427-432	1.5
Foitzik T, Schmidt J, Hotz HG, Warshaw AL, Buhr HJ, Klar E Effect of microcirculatory perfusion on distribution of trypsinogen activation in acute experimental pancreatitis. Dig Dis Sci 1995, 40: 2184-2188	17 1.5
.Hotz HG, Schmidt J, Ryschich E, Foitzik T, Buhr HJ, Herfarth C, Klar E Isovolemic hemodilution with dextran prevents contrast medium induced impairment of pancreatic microcirculation in necrotizing pancreatitis of the rat. Am J Surg 1995, 169: 161-166	20 2.1
Huch K, Schmidt J, Schrott W, Sinn HP, Buhr HJ, Herfarth C, Klar E Hyperoncotic dextran and systemic aprotinin in necrotizing rodent pancreatitis. Scand J Gastroenterol 1995, 30: 812-816	14 1.8
Mithöfer K, Schmidt J, Gebhard MM, Buhr HJ, Herfarth C, Klar E Measurement of blood flow in pancreatic exchange capillaries with FITC-labeled erythrocytes. Microvasc Res 1995, 49: 33-48	40 2.5

- Schmidt J, Huch K, Mithöfer K, Hotz HG, Sinn HP, Buhr HJ, Warshaw AL, Herfarth C, Klar E 8 4.41  
Benefits of various dextrans after delayed therapy in necrotizing pancreatitis of the rat.  
Intensive Care Med 1996, 22: 1207-1213
- Schmidt J, Klar E  
[Etiology and pathophysiology of acute pancreatitis].  
Ther Umsch 1996, 53:322-332
- Herzog L, Ryschich E, Schmidt J, Gebhard MM, Herfarth C, Klar E 1.5  
Octreotide reduces pancreatic blood flow in hypoperfused areas in acute pancreatitis.  
Langenbecks Arch Chir 1996, 113 Suppl 1: 407-411
- Werner J, Schmidt J, Gebhard MM, Herfarth C, Klar E 1.5  
Überlegenheit von Dextran gegenüber HAES und Kristalloiden in der Hemmung der Leukozyten-Endothel Interaktion bei experimenteller nekrotisierender Pankreatitis.  
Langenbecks Arch. Chir. 1996, 113 Suppl 1: 467-470
- Werner J, Hartwig W, Schmidt J, Gebhard MM, Herfarth C, Klar E 1.5  
Reduktion lokaler und systemischer Komplikationen der akuten Pankreatitis durch monoklonale Antikörper gegen ICAM-1.  
Langenbecks Arch Chir 1998, Suppl 1: 725-729
- Werner J, Schmidt J, Warshaw AL, Gebhard MM, Herfarth C, Klar E 19 7.7  
The relative safety of MRI contrast agent in acute necrotizing pancreatitis.  
Ann Surg 1998, 227: 105-111
- Schmidt J, Ryschich E, Sinn HP, Herfarth C, Klar E, Maksan S 6 1.5  
Trypsinogen activation peptides (TAP) in peritoneal fluid as predictors of late histopathologic injury in necrotizing pancreatitis of the rat.  
Dig Dis Sci 1999, 44: 823-829
- Werner J, Keck T, Schmidt J, Aulmann M, Kuntz C, Gebhard MM, Aulmann M, Klar E 1.5  
Akute Pankreatitis: Prädiktion schwerer und septischer Krankheitsverläufe mittels intramukosaler pH-Messung im Sigma. Acute pancreatitis: Prediction of severe and septic courses by noninvasive intramucosal pH-measurements of the sigma. Langenbecks Arch Chir 1999, 116 Suppl 1: 45-49
- Hartwig W, Werner J, Mayer H, Ryschich E, Schmidt J, Gebhard MM, Herfarth Ch, Klar E 11 2.1  
Cigarette smoke enhances ethanol-induced pancreatic injury.  
Pancreas 2000, 21: 272-279

- Alsfasser G, Gock , Herzog, Gebhard MM, Herfarth C, Klar E, Schmidt J 3 1.5  
 Glutathione depletion with L-buthionine-[S,R]-sulfoximine demonstrates deleterious effects in acute pancreatitis of the rat.  
 Dig Dis Sci 2002, 47:1793-1799
- Hartwig W, Maksan SM, Foitzik T, Schmidt J, Herfarth C, Klar E 26 2.27  
 Reduction in mortality with delayed surgical therapy of severe pancreatitis.  
 J Gastrointest Surg 2002, 6: 481-487
- Schmidt J, Werner J, Ebeling D, Mithöfer K, Ryschich E, Buhr HJ, Herfarth C, 13 2.04  
 Klar E  
 Pancreatic capillary blood flow in an improved model of acute necrotizing pancreatitis in the rat.  
 J Surg Res 2002, 106:335-341
- Paramythiotis D, Kleeff J, Schmidt J, Büchler MW, Friess H  
 Detection of oncogenes in chronic pancreatitis.  
 HPB (Oxford) 2003, 5:214-225
- Ryschich E, Kerkadze V, Deduchovas O, Salkinova O, Parseliunas A, Märten A, Hartwig W, Sperandio M, Schmidt J  
 Intracapillary leucocyte accumulation as a novel antihaemorrhagic mechanism in a pancreatitis in mice.  
 Gut 2009, 58: 1508-1516